Columbia University Medical Center
NewYork-Presbyterian Hospital The University Hospital of Columbia and Cornell
Nasal Spray Shows Promise for Binge Eating Disorder
May 31, 2013

 A novel, experimental intranasal spray formulation of naloxone is showing promise for the treatment of binge eating disorder (BED), preliminary research suggests.

Results from a phase II, randomized, double-blind, placebo-controlled trial presented here at the American Psychiatric Association's 2013 Annual Meeting showed that intranasal naloxone spray produced a significantly greater reduction than placebo in time spent binge eating (P = .024).

ead more: http://www.medscape.com/viewarticle/805004

 

chronos interior